AMRazor (formerly Rebiotics Rx) develops nanotechnology-based antibiotics with the focus on resistant bacteria
The World Health Organization has classified antimicrobial resistance (AMR) as a leading global health threat. It is estimated that antibiotic-resistant bacteria currently cause the death of 700,000 people, and that by 2050 the number of deaths will reach 10 million, exceeding the predicted number of cancer death in that year and would cost the world up to USD 100 trillion. Furthermore, in the absence of effective treatments the success of major surgeries and cancer chemotherapies would also be compromised owing to bacterial contamination.
The introduction of novel antibiotics from the laboratory to the patient is a lengthy and expensive process. At AMRazor such development is significantly simplified, owing to the faster and much cheaper "way to market” combined with greater chances of success. We identify existing antibiotics whose usefulness is limited owing to their short lifetimes, their rapid degradation, or their neutralization by binding to plasma proteins. We have the ability to overcome these major deficiencies by employing suitable delivery systems. As a result, "old” antibiotics that are chemically available at a clinical grade, and have known modes of action and toxicity characteristics, can rapidly reach the stage of clinical trials and eventually gain approval for AMR treatment.